ANAPTYSBIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.83 USD | -7.64% |
|
-19.81% | -7.42% |
| Apr. 16 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
| Apr. 11 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
Chart calendar AnaptysBio, Inc.
4e4de56221c5b7c2f.sCApOiGQ-peGOcUEyAAZloRMqlsVL9PhthGHapAylx8.iBRtW1TekqXydZRouFJr_vB62R5XHKKy12jfGqNz2WzhGXgOSd7Dz_xu8Q~dcd8aa51a60c107ebb8c4ebf13d04cb6
Upcoming events on AnaptysBio, Inc.
Past events on AnaptysBio, Inc.
| 2024-03-11 04:15 pm | Q4 2023 Earnings Release |
| 2024-03-08 12:30 pm | American Academy of Dermatology Meeting - Poster No:-50585 |
| 2024-03-05 02:10 pm | TD Cowen Health Care Conference |
| 2024-02-07 09:30 am | Guggenheim Healthcare Talks Biotechnology Conference |
| 2023-11-30 10:25 am | Evercore ISI HealthCONx Conference |
| 2023-11-29 02:00 pm | Piper Sandler Healthcare Conference |
| 2023-11-15 12:40 pm | Stifel Healthcare Conference |
| 2023-11-07 | UBS BioPharma Conference |
| 2023-11-07 09:50 am | Guggenheim I&I Conference |
| 2023-11-02 04:15 pm | Q3 2023 Earnings Release |
| 2023-10-25 04:15 pm | R&D Day |
| 2023-10-13 02:30 am | European Academy of Dermatology and Venereology Conference - Abstract No: 5603 |
| 2023-10-10 | European Academy of Dermatology and Venereology Conference - E-Poster No: P0558 |
| 2023-09-19 02:15 pm | Stifel Immunology & Inflammation Virtual Summit |
| 2023-08-07 04:15 pm | Q2 2023 Earnings Release |
| 2023-06-15 12:00 pm | Annual General Meeting |
| 2023-06-12 | Goldman Sachs Global Healthcare Conference |
| 2023-06-06 | Jefferies Global Healthcare Conference |
| 2023-05-25 04:15 pm | R&D Day |
| 2023-05-11 04:15 pm | Q1 2023 Earnings Release |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 8,00 7,00 14.29% | 75,0 71,7 4.65% | 63,2 173 -63.5% | 10,3 9,05 13.64% | 17,2 11,0 55.38% | 16,4 |
|
EBITDA Million USD | Released Forecast Spread | -107 -122 12.72% | -23,3 -72,9 68.01% | -56,2 120 -146.83% | -114 -109 -5.38% | -164 -153 -7.17% | -175 |
|
EBIT Million USD | Released Forecast Spread | -107 -120 10.81% | -23,9 -26,1 8.65% | -56,8 54,5 -204.24% | -115 -115 -0.15% | -164 -164 -0.29% | -178 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -97,5 -112 12.76% | -19,9 -21,5 7.49% | -57,8 31,3 -284.46% | -129 -126 -2.22% | -164 -167 1.89% | -181 |
|
Net income Million USD | Released Forecast Spread | -97,3 -112 12.73% | -20,3 -21,9 7.39% | -57,8 29,6 -295.18% | -129 -127 -1.49% | -164 -165 0.88% | -178 |
|
EPS USD | Released Forecast Spread | -3,60 -4,07 11.57% | -0,73 -0,81 9.89% | -2,11 1,74 -221.28% | -4,57 -4,53 -0.96% | -6,08 -6,07 -0.19% | -6,32 |
| Announcement Date | 02/03/20 | 25/02/21 | 07/03/22 | 01/03/23 | 11/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 1,01 111 -99.09% | 0,97 5,05 -80.81% | 1,22 5,61 -78.31% | 1,29 13,4 -90.37% | 6,81 5,86 16.28% | 1,37 2,88 -52.22% | 3,46 2,77 25.02% | 3,32 1,48 123.77% | 9,01 3,75 140.34% | 3,44 | 3,89 | 4,40 | 4,63 | 7,28 |
|
EBITDA Million USD | Released Forecast Spread | -31,0 106 -129.24% | -31,6 -21,5 -46.89% | -27,6 -28,0 1.3% | -29,5 -20,0 -47.34% | -25,8 -15,0 -71.93% | -44,2 -28,1 -57.14% | -40,0 -38,0 -5.21% | -42,0 -37,0 -13.43% | -47,0 | -46,0 | -45,0 | -43,0 | ||
|
EBIT Million USD | Released Forecast Spread | -31,2 80,1 -138.9% | -31,7 -27,7 -14.54% | -27,8 -26,8 -3.71% | -29,6 -16,4 -80.17% | -26,0 -26,1 0.64% | -44,4 -30,0 -47.76% | -40,1 -45,4 11.51% | -37,7 -47,8 21.03% | -42,1 -41,6 -1.18% | -42,6 | -43,8 | -44,8 | -46,5 | -45,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -32,5 56,7 -157.4% | -36,3 -28,0 -29.27% | -32,6 -28,1 -15.71% | -33,5 -15,8 -111.94% | -26,4 -26,5 0.27% | -44,3 -30,3 -46% | -39,8 -45,0 11.4% | -37,3 -46,7 20.04% | -42,2 -45,4 7.01% | -43,0 | -44,4 | -45,9 | -47,4 | -42,7 |
|
Net income Million USD | Released Forecast Spread | -32,5 54,9 -159.32% | -36,3 -28,1 -29.18% | -32,6 -28,2 -15.63% | -33,5 -15,9 -111.31% | -26,4 -26,5 0.18% | -44,3 -30,3 -46% | -39,8 -45,0 11.4% | -37,3 -46,7 20.04% | -42,2 -44,3 4.61% | -42,5 | -43,9 | -45,2 | -46,5 | -44,0 |
|
EPS USD | Released Forecast Spread | -1,18 2,57 -145.87% | -1,31 -0,99 -31.74% | -1,15 -1,01 -13.31% | -1,18 -0,62 -89.86% | -0,93 -0,96 2.82% | -1,58 -1,05 -50.65% | -1,50 -1,70 11.53% | -1,41 -1,82 22.46% | -1,59 -1,60 0.66% | -1,58 | -1,62 | -1,56 | -1,58 | -1,66 |
| Announcement Date | 07/03/22 | 04/05/22 | 08/08/22 | 08/11/22 | 01/03/23 | 11/05/23 | 07/08/23 | 02/11/23 | 11/03/24 | - | - | - | - | - |
More events
Past sector events for AnaptysBio, Inc.
| 2024-04-17 | BEIJING KAWIN TECHNOLOGY SHARE-HOLDING CO., LTD.: Q1 2024 Earnings Release (Projected) |
| 2024-04-17 | JIANGSU YAHONG MEDITECH CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-12 | SINOCELLTECH GROUP LIMITED: Q4 2023 Earnings Release |
| 2024-04-10 07:00 am | NURIX THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-04-08 | MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-02 03:06 am | TAIMED BIOLOGICS INC.: March 2024 Sales and Revenue Release |
| 2024-03-31 | PEPTRON, INC.: Q4 2023 Earnings Release (Projected) |
| 2024-03-31 | BIONEER CORPORATION: Q4 2023 Earnings Release (Projected) |
| 2024-03-29 08:30 am | INNOCARE PHARMA LIMITED: Q4 2023 Earnings Release |
| 2024-03-28 | BIO-THERA SOLUTIONS, LTD.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ANAB Stock
- Calendar AnaptysBio, Inc.
